U.S. Sex Reassignment Hormone Therapy Market Share

U.S. Sex Reassignment Hormone Therapy Market Share

The market has been dominated by fierce competition. It is extremely fragmented due to the existence of both major and small firms. Major firms hold a sizable share of the market. To increase product penetration and grow their client base, major firms use a variety of techniques, including new product launches, acquisitions, partnerships, collaborations, and expansions.
 

U.S. Sex Reassignment Hormone Therapy Market Companies

Some of the eminent market participants operating in the U.S. sex reassignment hormone therapy industry include:

• ASCEND Therapeutics US, LLC
• BIOTE MEDICAL, LLC
• Eli Lilly and Company
• Endo International plc
• Novartis AG
• Noven Pharmaceuticals, Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.